Author

Edmund K. Waller

Emory University - Cited by 24,970 - transplantation - immunology - stem cells - cancer

Biography

Edmund K. Waller, belonging to Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA. Interested in the field of Autologous stem cell transplantation, Health disparity.
Title
Cited by
Year
Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing
M Qayed, JP McGuirk, GD Myers, V Parameswaran, EK Waller, P Holman, ...Cytotherapy 24 (9), 869-878, 2022202
10
2022
Donor plasmacytoid dendritic cells limit graft-versus-host disease through vasoactive intestinal polypeptide expression
J Zhu, Y Wang, J Li, PK Das, H Zhang, T Passang, JM Li, T Nagy, ...Blood, The Journal of the American Society of Hematology 140 (12), 1431-1447, 2022202
6
2022
Secondary neoplasms after hematopoietic cell transplant for sickle cell disease
M Eapen, R Brazauskas, DA Williams, MC Walters, A St Martin, BL Jacobs, ...Journal of Clinical Oncology 41 (12), 2227-2237, 2023202
5
2023
Precision-engineered cell therapy Orca-T demonstrates high relapse-free survival at 1 year while reducing graft-versus-host disease and toxicity
C Oliai, RT Hoeg, A Pavlova, A Gandhi, L Muffly, RS Mehta, SA Srour, ...Blood 140 (Supplement 1), 64-66, 2022202
5
2022
A randomized trial of topical fibrinogen-depleted human platelet lysate treatment of dry eye secondary to chronic graft-versus-host disease
A Sugar, M Hussain, W Chamberlain, R Dana, DP Kelly, C Ta, J Irvine, ...Ophthalmology science 2 (3), 100176, 2022202
4
2022
Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study
DB Miklos, MA Zaid, JP Cooney, JC Albring, M Flowers, AP Skarbnik, ...Journal of Clinical Oncology 1 (10), 1876, 2023202
4
2023
Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma
S Ravindranathan, T Passang, JM Li, S Wang, R Dhamsania, MB Ware, ...Nature Communications 1 (1), 6418, 2022202
3
2022
Safety of autologous freshly expanded mesenchymal stromal cells for the treatment of graft-versus-host disease
E Stenger, CR Giver, A Langston, D Kota, PK Das, R Chinnadurai, ...Frontiers in Immunology 13, 959658, 0
2
2022
Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results
U Jaeger, N Worel, JP McGuirk, PA Riedell, I Fleury, Y Du, X Han, ...Blood Advances 7 (11), 83-86, 030
2
2023
Orca-Q Demonstrates Favorable GvHD-and-Relapse-Free Survival in Haploidentical Transplants without Post-Transplant Cyclophosphamide
A Salhotra, SA Srour, RT Hoeg, A Saad, EH Meyer, A Pavlova, EK Waller, ...Blood 140 (Supplement 1), 1865-1866, 0
2
2022
CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation …
CTX0 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase Dose Escalation …JP McGuirk, CS Tam, N Kröger, PA Riedell, HS Murthy, PJ Ho, ...Blood 40 (Supplement ), 0303-0306, 2022202
1
2022
CT-524 Orca-T, A Precision Engineered Allograft, Results in High GVHD-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies
E Meyer, A Pavlova, A Gandhi, R Hoeg, C Oliai, R Mehta, S Srour, ...Clinical Lymphoma Myeloma and Leukemia 22, S447, 2022202
1
2022
Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD)
Neihulizumab (ALTB-68) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD)S Abedin, M Hamadani, SG Holtan, GJ Schiller, M Gallogly, EK Waller, ...Blood 40 (Supplement ), 0495-0497, 2022202
1
2022
The association between baseline circulating progenitor cells and vascular function: The role of aging and risk factors
K Moazzami, A Mehta, A Young, DS Dhindsa, G Martin, A Mokhtari, ...Vascular Medicine 27 (6), 532-54, 2022202
1
2022
mTOR inhibition attenuates cTfh cell dysregulation and chronic T-cell activation in multilineage immune cytopenias
D Kumar, TH Nguyen, CM Bennett, C Prince, L Lucas, S Park, T Lawrence, ...Blood, The Journal of the American Society of Hematology 4 (3), 238-243, 2023202
1
2023
Circulating progenitor cells and outcomes in patients with coronary artery disease
DS Dhindsa, SR Desai, Q Jin, PB Sandesara, A Mehta, C Liu, AS Tahhan, ...International Journal of Cardiology 373, 7-6, 2023202
1
2023
Final safety and efficacy results from Equate, an open-label study evaluating itolizumab, a novel targeted anti-CD6 therapy, in newly diagnosed acute graft-versus-host disease
J Koreth, AW Loren, R Nakamura, EK Waller, JA Pidala, M Mielcarek, ...2023 Tandem Meetings| Transplantation & Cellular Therapy Meetings of ASTCT …, 2023202
1
2023
The magic of small-molecule drugs during ex vivo expansion in adoptive cell therapy
H Zhang, T Passang, S Ravindranathan, R Bommireddy, MR Jajja, ...Frontiers in Immunology 4, 54566, 2023202
1
2023

Referred From: https://scholar.google.com/citations?user=ZwhScmYAAAAJ&hl=en

Cited by
Citations 24970
h-index 82
i10-index 288
Recommended Journals
Open Access Journals